

[← News](#)

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025

17 January 2025

Investigation of risk of rare eye condition with
semaglutide medicines

[News](#)[Human](#)[Medicines](#)[Pharmacovigilance](#)[Referrals](#)



Page contents



Medicines containing semaglutide: PRAC investigating risk of rare eye condition

PRAC will assess risk of non-arteritic anterior ischemic optic neuropathy (NAION)

EMA's safety committee, [PRAC](#), has started a review of medicines containing semaglutide following concerns regarding an increased risk of developing NAION, a rare eye condition, as suggested in two recent observational studies, while two other recent observational studies do not suggest an increased risk.

Semaglutide, a GLP-1 receptor agonist, is the [active substance](#) in certain medicines used in the treatment of diabetes and obesity (namely [Ozempic](#), [Rybelsus](#) and [Wegovy](#)).

[PRAC](#) is assessing whether patients treated with semaglutide may have an elevated risk of developing NAION. This is a disorder caused by reduced blood flow to the optic nerve in the eye with potential damage to the nerve, which can lead to loss of vision in the affected eye. Patients with type 2 diabetes might already have an inherently higher risk of developing this condition.

[PRAC](#) will now review all available data on NAION with semaglutide including data from [clinical trials](#), post-marketing surveillance, studies on the mechanism of action and the medical literature (including the results of the observational studies).

EMA will communicate further when appropriate.

References:

- Chou CC, Pan SY, Sheen YJ, Lin JF, Lin CH, Lin HJ, Wang

IJ, Weng CH. [Association between Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Real-World Study.](#)

Ophthalmology. 2024 Nov 2: S0161-6420(24)00685-7. doi: 10.1016/j.ophtha.2024.10.030. Epub ahead of print. PMID: 39491755.

- Klonoff DC, Hui G, Gombar S. [Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.](#) J Diabetes Sci Technol 2024: 19322968241268050.
- Grauslund, J., Abou Taha, A., Dehghani Molander, L., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L., [Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes,](#) *International Journal of Retina and Vitreous*, accepted for publication.
- Simonsen E., Lund LC, Thomsen Ernst M., Hjellvik V., Hegedüs L., Hamann S., Kalsnes Jørstad Ø., Løvdal Gulseth H., Karlstad Ø., Pottegård A., 2024 Dec 11 [Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study](#) medRxiv preprint doi: 10.1101/2024.12.09.24318574

Agenda



Agenda of the PRAC meeting 13-16 January 2025

Draft


Reference Number: EMA/PRAC/549682/2024

English (EN) (736.35 KB - PDF)

First published: 13/01/2025

[View](#)

PRAC statistics: January 2025



PRAC statistics: January 2025

English (EN) (107.97 KB - PDF)

First published: 17/01/2025

[View](#)

Glossary

- **Safety signal assessments.** A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine and an adverse event that warrants further investigation. Safety signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. More information can be found under '[Signal management](#)'.
- **Periodic safety update reports,** abbreviated as PSURs, are reports prepared by the marketing authorisation holder to describe the worldwide safety experience with a medicine in a defined period after its authorisation. PSURs for medicinal products that contain the same active substance or the same combination of active substances but have different marketing authorisations and are authorised in different EU Member States, are jointly assessed in a single assessment procedure. More information can be found under '[Periodic safety update reports: questions and answers](#)'.
- **Risk management plans,** abbreviated as RMPs, are detailed descriptions of the activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicines. Companies are required to submit an RMP to EMA when applying for a marketing authorisation. RMPs are continually updated throughout the lifetime of the medicine as new information becomes available. More information is available under '[Risk-management plans](#)'.
- **Post-authorisation safety studies,** abbreviated as PASSs, are studies carried out after a medicine has been authorised to obtain further information on its safety, or to measure the effectiveness of risk-management measures. The PRAC assesses the protocols (aspects related to the organisation of a study) and the results of PASSs. More information can be found under '[Post-authorisation safety studies](#)'.
- **Referrals** are procedures used to resolve issues such as concerns over the safety or benefit-risk balance of a

medicine or a class of medicines. In a [referral](#) related to safety of medicines, the [PRAC](#) is requested by a Member State or the European Commission to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. More information can be found under [referral procedures](#).

Ongoing referrals

Procedure	Status	Update
Finasteride- and dutasteride-containing medicinal products - referral	Under evaluation	PRAC continued its assessment

Related content

[Pharmacovigilance Risk Assessment Committee \(PRAC\): 13-16 January 2025](#)

[Pharmacovigilance Risk Assessment Committee \(PRAC\)](#)

Related documents



Abbreviations used in EMA scientific committees and CMD documents, and in relation to EMA’s regulatory activities

Reference Number: EMA/899164/2022

English (EN) (434.08 KB - PDF)

First published: 05/10/2012

Last updated: 02/12/2024

[View](#)

Contact point

Media enquiries

Tel. +31 (0)88 781 8427

E-mail: press@ema.europa.eu

All other enquiries

please submit your request via the [online form](#)

Follow us on X [@EMA_News](#)

Related content

- [Finasteride- and dutasteride-containing medicinal products - referral](#)
- [Ozempic](#)
- [Rybelsus](#)
- [Wegovy](#)

Topics

[Medicines](#)

[Pharmacovigilance](#)

[Referrals](#)

Share this page

 E-mail  LinkedIn  X  Facebook

 More share options

**Product emergency hotline
OUTSIDE WORKING HOURS**

About us

What we do

Careers

Committees & working parties

Regulatory network

[European experts](#)

[Languages](#)

[Frequently asked questions](#)

[Glossaries](#)

[About this website](#)

[Cookies](#)

[Website data protection notice](#)

[Data protection at EMA](#)

[Search tips](#)

[Access to documents](#)

[Contacts](#)

[Send a question](#)

[EMA Service Desk \(system support\)](#)

[Services and databases](#)

[European Medicines Agency](#)

[Domenico Scarlattilaan 6](#)

[1083 HS Amsterdam](#)

[The Netherlands](#)

[Tel: +31 \(0\)88 781 6000](#)

[How to find us](#)

[Postal address and deliveries](#)

[Business hours and holidays](#)

[RSS Feed](#)

[X](#)

[YouTube](#)

[LinkedIn](#)

© 1995 - 2025 European Medicines Agency

European Union agencies network

An agency of the European Union